The CheckMate 648 study compared first-line therapy of anti-PD-1-antibody nivolumab plus chemotherapy or plus anti-CTLA-4 antibody ipilimumab to chemotherapy alone in patients with advanced or metastatic ESCC. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.